Negative design for improved therapeutic proteins.
D000818:Animals; D015195:Drug Design; D004345:Drug Industry / Q000379:methods / Q000639:trends; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy* / Q000378:metabolism; D011486:Protein C / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D015202:Protein Engineering / Q000379:methods*; D011506:Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000639:trends
D011486:Protein C; D011506:Proteins; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C421124:drotrecogin alfa activated; D000069585:Filgrastim